1. Home
  2. SOS vs KALA Comparison

SOS vs KALA Comparison

Compare SOS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$0.36

Market Cap

14.9M

Sector

Finance

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.48

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOS
KALA
Founded
2004
2009
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
13.3M
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
SOS
KALA
Price
$0.36
$0.48
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $31.50
AVG Volume (30 Days)
★ 2.5M
376.1K
Earning Date
05-15-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 67.39
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.07
52 Week High
$2.35
$3.96

Technical Indicators

Market Signals
Indicator
SOS
KALA
Relative Strength Index (RSI) 26.88 33.57
Support Level N/A $0.35
Resistance Level $1.10 $0.72
Average True Range (ATR) 0.16 0.05
MACD -0.04 0.01
Stochastic Oscillator 7.95 0.07

Price Performance

Historical Comparison
SOS
KALA

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: